Biopore

Biopore is a biotechnology company specializing in the use of the nematode Caenorhabditis elegans as a model organism for drug discovery and the validation of health-promoting compounds. The company provides a high-throughput screening platform that allows for the rapid evaluation of toxicity, efficacy, and mechanism of action for pharmaceutical, nutraceutical, and cosmetic candidates. Biopore's technology is particularly focused on therapeutic areas such as neurodegeneration, metabolic disorders, and longevity, offering a biological bridge between in vitro assays and mammalian animal models. Founded as a spin-off from the University of Valencia, the company was acquired by ADL Bionext in 2017 and subsequently became part of Wacker Chemie in 2023.